Equities Analysts Set Expectations for CryoPort Q2 Earnings

CryoPort, Inc. (NASDAQ:CYRX - Free Report) - Analysts at Leerink Partnrs lifted their Q2 2025 EPS estimates for shares of CryoPort in a report issued on Thursday, July 17th. Leerink Partnrs analyst P. Souda now anticipates that the company will post earnings of ($0.19) per share for the quarter, up from their previous forecast of ($0.21). The consensus estimate for CryoPort's current full-year earnings is ($0.99) per share. Leerink Partnrs also issued estimates for CryoPort's Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.79) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.14) EPS and FY2026 earnings at ($0.68) EPS.

CryoPort (NASDAQ:CYRX - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. The firm had revenue of $41.04 million during the quarter, compared to analysts' expectations of $56.19 million. CryoPort had a negative net margin of 50.15% and a negative return on equity of 11.03%.

A number of other research firms also recently commented on CYRX. Stephens raised shares of CryoPort to an "overweight" rating and set a $13.00 price objective for the company in a research note on Tuesday. BTIG Research reduced their price objective on CryoPort from $13.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, July 7th. Roth Mkm reaffirmed a "buy" rating and issued a $15.00 target price on shares of CryoPort in a research report on Tuesday, April 1st. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 target price on shares of CryoPort in a report on Thursday, May 8th. Finally, Morgan Stanley decreased their price objective on CryoPort from $8.00 to $7.00 and set an "equal weight" rating for the company in a research report on Monday, May 5th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $11.11.

CryoPort Stock Performance

Shares of CryoPort stock traded up $0.51 during trading on Monday, reaching $8.32. The company's stock had a trading volume of 126,470 shares, compared to its average volume of 451,742. The company has a 50-day moving average price of $6.87 and a two-hundred day moving average price of $6.63. CryoPort has a fifty-two week low of $4.58 and a fifty-two week high of $9.66. The company has a current ratio of 5.56, a quick ratio of 5.24 and a debt-to-equity ratio of 0.51. The firm has a market cap of $416.91 million, a PE ratio of -3.56 and a beta of 1.89.

Insider Transactions at CryoPort

In other news, Director Ramkumar Mandalam sold 13,321 shares of the firm's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $7.01, for a total value of $93,380.21. Following the completion of the transaction, the director directly owned 73,056 shares of the company's stock, valued at $512,122.56. This trade represents a 15.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert J. Hariri sold 12,500 shares of the stock in a transaction on Wednesday, May 28th. The stock was sold at an average price of $6.10, for a total value of $76,250.00. Following the completion of the sale, the director owned 8,061 shares in the company, valued at $49,172.10. This trade represents a 60.79% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 449,719 shares of company stock worth $3,042,327. 10.00% of the stock is currently owned by insiders.

Institutional Trading of CryoPort

Several large investors have recently modified their holdings of the business. Thrivent Financial for Lutherans purchased a new position in CryoPort in the 4th quarter worth approximately $299,000. American Century Companies Inc. boosted its holdings in CryoPort by 12.0% in the 4th quarter. American Century Companies Inc. now owns 51,443 shares of the company's stock worth $400,000 after buying an additional 5,508 shares during the period. Fox Run Management L.L.C. bought a new position in shares of CryoPort during the 4th quarter valued at about $111,000. LPL Financial LLC boosted its holdings in shares of CryoPort by 1,366.1% during the 4th quarter. LPL Financial LLC now owns 436,766 shares of the company's stock valued at $3,398,000 after purchasing an additional 406,976 shares during the last quarter. Finally, Perkins Capital Management Inc. lifted its holdings in shares of CryoPort by 1,286.1% in the 4th quarter. Perkins Capital Management Inc. now owns 159,400 shares of the company's stock valued at $1,240,000 after acquiring an additional 147,900 shares during the last quarter. 92.90% of the stock is owned by institutional investors.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.